Phase 3 Parkinson's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with high-risk, early-stage breast cancer that has not spread to other parts of the body (non-metastatic), and whose tumor and lymph node involvement falls within specific size and spread categories as assessed by their doctor using scans or physical examination
• People whose breast cancer has been confirmed by a central laboratory to be either triple-negative or a specific low-hormone-receptor type that is also HER2-negative
• People who are able to provide a core needle biopsy sample from the main breast tumor at the screening stage
• People who have a good general level of physical functioning, as measured by a standard medical scale (score of 0 or 1), assessed within 28 days before starting treatment
• People whose heart, liver, kidneys, and other organs are functioning well enough to meet the study's requirements

Who may not be able to join:

• People whose breast cancer has spread to distant parts of the body (Stage IV), or who have extensive lymph node involvement in a specific advanced category (cN3)
• People who have already received any treatment for their currently diagnosed breast cancer, including radiation, drug therapy, or surgery
• People who have already had surgery to remove the main tumor, full removal of underarm lymph nodes, or a sentinel lymph node biopsy before the study treatment begins
• People who have received any systemic cancer treatment, including experimental therapies, within 4 weeks before the study start date
• People who have previously been treated with certain types of immune checkpoint therapies targeting PD-1, PD-L1, PD-L2, or similar immune system pathways (such as CTLA-4, OX-40, or CD137)
• People who have previously received a specific type of targeted drug called a TROP2-targeted antibody-drug conjugate (ADC)
• People who have previously received a treatment containing a topoisomerase I inhibitor delivered via an antibody-drug conjugate (ADC)
• People who have received a live or live-attenuated vaccine within 30 days before the first dose of the study treatment
• People who have another cancer that is still active or has required treatment within the past 5 years
• People with a serious, uncontrolled illness affecting the whole body
• People who have a history of, or are currently experiencing, a non-infectious lung condition involving inflammation or scarring (such as pneumonitis or interstitial lung disease) that required steroid treatment, or where such a condition cannot be ruled out at screening

Important: Always verify eligibility with the trial site directly before applying.